Inside the White House with D.C.'s most wired reporter. Sign up for Mike Allen's Axios AM.


Merck will lower prices of some drugs

Merck headquarters building in New Jersey.
Merck headquarters in New Jersey. Photo: Kena Betancur/Getty Images

Merck said Thursday it is lowering the prices of a handful of unnamed drugs by 10% and dropping the price of hepatitis C medication Zepatier by 60%. The pharmaceutical company also said it would cap the "average net price" of some drugs at inflation.

Between the lines: Merck's moves come right after Novartis and Pfizer made separate pricing decisions. However, while lower list prices will help patients, Merck can still raise prices whenever it wants. And the 60% price cut to Zepatier won't matter a lot because Zepatier has lost considerable market share to other hepatitis C drugs.